%0 Journal Article %A Philip Koliopoulos %A Julius Jurak %A Sebastian Schlotter %A Oliver Nitsche %A Kristin Bohn %A Daniel Schreiner %A Stephan Gehring %A Krystyna Poplawska %T Use of BIOFIRE® Pneumonia Panel Plus on sputum from patients with Cystic fibrosis or PCD %D 2020 %R 10.1183/13993003.congress-2020.694 %J European Respiratory Journal %P 694 %V 56 %N suppl 64 %X Background: PCD and Cystic fibrosis are associated with chronic pulmonary infections. Pseudomonas aeruginosa (PA) or S. aureus (SA) cause a decline of lung function and determine antibiotic therapy. Viral infections influence onset of CF exacerbation. The BIOFIRE® Pneumonia Panel Plus comprises semiquantitative detection of 15 bacteria, 7 antibiotic resistance markers and 9 viruses.Aims: Can Biofire® POCT contribute to the early detection of CF-pathogens? We hypothesized a sensitive detection of PA and SA species as well as viral coinfections.Methods: From July - December 2019 sputum samples from in- or outpatients with CF or PCD were collected. Basic demographic and clinical data were obtained. Each sputum sample underwent Biofire® Pneumonia Panel Plus and culture-based testing.Results: 17 out- and 10 inpatients’ sputum samples were tested. 78% (21/27) had already received antibiotic treatment. POCT Biofire® detected viral coinfection in 8 cases. 19 samples were culture positive for PA, of which only 14 were detected by POCT. 17 were culture-positive for SA, of which 16 were detected by POCT. In 7 cases antibiotic resistance markers (mecA/C, MREJ) were found. The mean duration obtaining culture results was 9 days.Method: The POCT Biofire® showed ambiguous results detecting CF-pathogens. Concordance rate for PA was substantial and for SA good, according to Cohen’s kappa. The sensitivity of 73.7 % for PA might be due to false-negative classification when pathogens’ copies are quantified < 10^4/ml. The extended period to obtain culture results poses a limitation in clinical routine. POCT tools can be valuable screening for MRSA or viral coinfections.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 694.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). %U